Table 2.

MR analysis between exposure (cancers) and outcome (PD)

Exposure	N, SNPs included	r2	F-statistics	MR Egger			Inverse variance weighted
				b	se	p	b	se	p
Breast cancer	107	0.016	38.5	0.075	0.065	0.247	0.032	0.033	0.337
Chronic lymphocytic leukemia	7	0.035	106.11	0.047	0.640	0.944	0.099	0.077	0.197
Colorectal cancer	35	0.02	53.8	−0.002	0.273	0.994	0.042	0.057	0.460
Cutaneous squamous cell carcinoma	23	0.03	405.2	−0.097	0.077	0.223	0.051	0.048	0.288
Combined analysis of keratinocyte cancers	68	0.023	216.6	−0.018	0.053	0.732	0.017	0.031	0.586
Endometrial cancer	13	0.028	271.4	−0.106	0.252	0.681	−0.014	0.059	0.808
Lung cancer	10	0.029	120.4	0.000	0.121	0.999	0.049	0.053	0.355
Lymphoma	5	0.047	236.2	0.325	0.288	0.341	−0.013	0.068	0.845
Melanoma	45	0.026	244.37	−0.035	0.053	0.507	−0.002	0.032	0.950
Non-glioblastoma glioma/Glioma	19	0.052	88.03	0.102	0.049	0.052	−0.021	0.023	0.356
Oral cavity and pharyngeal cancer	4	0.059	198.2	0.008	0.376	0.986	0.094	0.064	0.144
Pancreatic cancer	16	0.037	68.9	−0.221	0.152	0.168	0.003	0.041	0.934
Prostate cancer	74	0.02	38.9	−0.091	0.060	0.130	−0.022	0.028	0.443
Renal cell carcinoma	8	0.028	148.02	−0.145	0.241	0.569	−0.031	0.084	0.707
Uterine fibroids	18	0.024	732.5	0.164	0.185	0.388	−0.014	0.073	0.854

PD, Parkinson’s disease; N, number; r², proportion of variance in exposure variable explained by SNPs; F, statistics ‘strength’ of the genetic instrumental variable; b, beta; se, standard error, p, p-value.